Back to Best of 2018 - Clinicians managing immune related adverse events with immune checkpoint inhibitors and Overcoming the blood brain barrier: new opportunities for treatment of brain metastases in non-small cell lung cancer
Best of 2018 - Clinicians managing immune related adverse events with immune checkpoint inhibitors and Overcoming the blood brain barrier: new opportunities for treatment of brain metastases in non-small cell lung cancer

Best of 2018 - Clinicians managing immune related adverse events with immune checkpoint inhibitors and Overcoming the blood brain barrier: new opportunities for treatment of brain metastases in non-small cell lung cancer

Speakers:

Christopher Campen, PharmD BCOP

Samantha N. Reiss, PharmD BCOP

Product Details

Practical Issues for Clinicians Managing Immune-Related Adverse Events with Immune Checkpoint Inhibitors

In this presentation we will review key concepts in the management of immunotherapy toxicities. We will use case-based examples to define common and uncommon toxicities of immunotherapy, review differences between single-agent and combination immunotherapy, and discuss management strategies for immunotherapy toxicities. The target audience is pharmacists working in clinical practice.

Overcoming the Blood-Brain Barrier: New Opportunities for Treatment of Brain Metastases in Non-Small-Cell Lung Cancer

Lung cancer is the leading cause of death in the United States, and brain metastases are a frequent complication of NSCLC, with about 25%–40% of patients developing brain metastases. Many firstgeneration tyrosine kinase inhibitors (TKIs) for treatment of epidermal growth factor receptor (EGFR)–and anaplastic lymphoma kinase (ALK)–mutant lung cancers have poor blood-brain barrier penetration, allowing the central nervous system (CNS) to serve as a sanctuary site of disease. With advances in treatment, many second- and third- generation TKIs, such as osimertinib, alectinib, and brigatinib, have increased blood-brain barrier permeability and have been shown effective in controlling and treating CNS metastases. This presentation will review the pathophysiology of the blood-brain barrier and mechanisms of permeation of oncologic agents to cross the blood-brain barrier; compare EGFR TKIs’ and ALK TKIs’ pharmacokinetics, cerebrospinal fluid penetration, and safety profile; and provide evidence-based literature on TKIs’ intracranial efficacy.

  • List Price: $35.00 USD
  • Member Price: $25.00 USD
Join and Save!
Log into see if you qualify for a lower price.
HOPA members save $10.00 USD or more!
Become a member